Today's drugs have somewhat solved a similar problem that the GLP1 presents, which is that it vanishes from the body quickly. But one of the ways they were able to delay it vanishing comes from scientists studying animal venoms. The first GLP1 receptor agonist was derived from heelomoster venom. Novo Nordisk and Eli Lilly solve the problem in different ways.
Weight loss drug sales are estimated to hit $44 billion by 2030. Many of these treatments can thank previously obscure research on a carnivorous deep sea fish for their development. Rolfe Winkler is a reporter for the Wall Street Journal covering digital health. Ricky Mulvey caught up with Winkler to discuss: - The origins and science behind weight loss drugs. - The challenge of selling lizard venom research to pharmaceutical companies. - What decades-old research on anglerfish reveals about modern side effects for Ozempic. - And why it’s “not too hard” to keep dozens of Gila Monsters in your basement. “Monster Diet Drugs Like Ozempic Started With Actual Monsters”: https://www.wsj.com/articles/ozempic-mounjaro-gila-monster-anglerfish-8c9c1ff2 Companies mentioned: NVO, LLY Host: Ricky Mulvey Guest: Rolfe Winkler Engineers: Tim Sparks, Heather Horton
Learn more about your ad choices. Visit megaphone.fm/adchoices